Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients
about
Pimecrolimus 1% cream for anogenital lichen sclerosus in childhoodChiral Alkyl Halides: Underexplored Motifs in MedicinePimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infantsApplication of concentrated deep sea water inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice.Relative efficacy of pimecrolimus cream and triamcinolone acetonide paste in the treatment of symptomatic oral lichen planusPimecrolimus for the treatment of inflammatory skin disease.Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Role of serum interleukin-6 in deciding therapy for multidrug resistant oral lichen planus.Problem-based learning: a review of current issues relevant to physiotherapy education.Atopic eczema: what's new?Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus.Is pimecrolimus cream (1%) an appropriate therapeutic agent for the treatment of external ear atopic dermatitis?Review of pimecrolimus cream 1% in children for the treatment of mild to moderate atopic dermatitis.A systematic review of the safety of topical therapies for atopic dermatitis.Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.Topical pimecrolimus 1% cream in the treatment of seborrheic dermatitis.Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.Skin absorption through atopic dermatitis skin: a systematic review.Pimecrolimus cream 1% in the treatment of lichen sclerosus.Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis.Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial.Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.Diagnosis and management of common dermatoses in children: atopic, seborrheic, and contact dermatitis.Low systemic exposure in infants with atopic dermatitis in a 1-year pharmacokinetic study with pimecrolimus cream 1%*.A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.Topical pimecrolimus effect on Fas inducing apoptosis in oral lichen planus: a clinical immunohistochemical study.
P2860
Q24791867-D589873B-05D5-4E1F-9CB6-F984653894F8Q28066955-CAB39CEF-BF11-44DE-AB8E-ED1424D4EB97Q28086973-3721B71E-6D2D-4F3E-B19A-A02B750DF08FQ34352738-52F8C8C1-49C0-4C80-9615-7EFA036E8DCDQ35169829-07300C14-8FA4-4B7D-B953-954A7D3ABB58Q35688189-83ECEB1A-37FD-4AAF-9C39-1EE96729161CQ36222741-5DE87AC8-B159-45E5-8221-1D2A82ADB2FEQ36236612-A17BBF9A-8A2E-406C-8BF0-835039665044Q36356956-069BCA19-A0C7-4ADE-9425-F34A0211EC4DQ36473293-0651C185-D7E7-4F98-A8E0-A58AF23882BAQ36574341-2F97C79B-E819-4EA2-8AEE-8237F46AAB3DQ36577730-FCC38ECF-98DA-4BB6-AF83-D2BC56DE4657Q36681795-F2934DE0-C712-4DA3-B339-6CD33BF657ADQ36708358-E3603827-6C27-4577-ACDB-2F9168F1BE7DQ36861654-1682C953-9845-446D-AC64-FA84FD75F119Q36892767-7A466ABA-E730-4FB8-8BB6-A56EE80383BFQ37049981-1919BC18-39E2-4270-A539-ED5661C96365Q37049990-3560EAC7-6AC7-45BB-951F-29638CB06441Q38084638-F2DF770E-D975-429D-8BA0-DD18486E99A5Q38123240-C7ADAB74-9299-49E9-A2F5-6C7522B42389Q38957449-78029B8D-6259-45E9-BB11-0E7DEF2CA194Q39343884-D1D3DB0F-3AE5-41B9-BA7E-C0426A73C30DQ42164135-1E97A620-BEAC-4FCB-88A5-04BB2C89419FQ46701419-197606C5-7FE9-4852-A369-84BC206BD955Q46725937-4AB10201-F686-43CC-946B-B5D521E18F08Q46868092-518753CE-EE50-4A26-8FBC-23B1A8F2C24CQ46909164-23606105-8DD1-42E8-9547-E5BB0FAE9CBAQ46951905-417D9090-B0AD-4DD8-95B9-82079CA14276Q50993513-21F66BC6-8344-4F91-B941-4AF476401CCC
P2860
Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Systemic exposure, tolerabilit ...... in atopic dermatitis patients
@ast
Systemic exposure, tolerabilit ...... in atopic dermatitis patients
@en
Systemic exposure, tolerabilit ...... in atopic dermatitis patients
@nl
type
label
Systemic exposure, tolerabilit ...... in atopic dermatitis patients
@ast
Systemic exposure, tolerabilit ...... in atopic dermatitis patients
@en
Systemic exposure, tolerabilit ...... in atopic dermatitis patients
@nl
prefLabel
Systemic exposure, tolerabilit ...... in atopic dermatitis patients
@ast
Systemic exposure, tolerabilit ...... in atopic dermatitis patients
@en
Systemic exposure, tolerabilit ...... in atopic dermatitis patients
@nl
P2093
P2860
P356
P1476
Systemic exposure, tolerabilit ...... in atopic dermatitis patients
@en
P2093
M Lakhanpaul
M-E Ebelin
T J Stephenson
P2860
P304
P356
10.1136/ADC.88.11.969
P407
P577
2003-11-01T00:00:00Z